Levothyroxine generic name
Pro Research Analysisby 
Searched over 200M research papers
Levothyroxine Generic Name: Clinical Implications and Bioequivalence
Introduction to Levothyroxine and Its Generic Forms
Levothyroxine, commonly known by its brand name Synthroid, is a synthetic form of the thyroid hormone thyroxine (T4) used to treat hypothyroidism. It is available in various formulations, including tablets, soft gel capsules, and oral solutions, and can be found in both brand-name and generic versions . The generic name for this medication is levothyroxine sodium.
Bioequivalence of Generic and Brand-Name Levothyroxine
FDA Bioequivalence Standards
The U.S. Food and Drug Administration (FDA) has established protocols to determine the bioequivalence of generic levothyroxine products. These protocols primarily focus on serum thyroxine (T4) levels after a single oral dose in healthy volunteers . However, this method has faced criticism for not considering serum thyroid-stimulating hormone (TSH) levels and for initially not correcting baseline T4 levels . Despite these concerns, the FDA's criteria for bioequivalence are stringent, requiring a 90% confidence interval within 0.8-1.25 for the area under the curve (AUC) and peak serum concentrations .
Clinical Studies on Bioequivalence
Several studies have investigated the bioequivalence of generic and brand-name levothyroxine. A single-blind, randomized, 4-way crossover trial involving 22 women with hypothyroidism found no significant differences in the AUC or peak serum concentrations of total thyroxine, total triiodothyronine, or free thyroxine index among four levothyroxine products, including two generics and two brand names . This study concluded that the products were bioequivalent and interchangeable for most patients .
Clinical Implications of Generic Substitution
Pediatric and Vulnerable Populations
The bioequivalence of generic levothyroxine has been questioned, particularly in vulnerable populations such as children with severe congenital hypothyroidism (CH). A study involving 31 children with severe hypothyroidism found that the serum TSH concentration was significantly lower after 8 weeks of treatment with Synthroid compared to a generic formulation . This difference was particularly pronounced in children with CH, suggesting that generic levothyroxine may not be bioequivalent in this subgroup . Another study found that generic levothyroxine provided similar or better control of hypothyroidism in young children with CH compared to Synthroid, as measured by TSH variance and the frequency of dose adjustments .
Real-World Evidence and Safety Concerns
A systematic review of post-marketing studies highlighted mixed findings regarding the effectiveness and safety of generic levothyroxine compared to brand-name products . Some studies reported suboptimal medication adherence and potential safety concerns with generic formulations, while others found no significant differences in clinical outcomes . Additionally, there have been reports of severe hypothyroidism resulting from the use of generic levothyroxine, attributed to lower-than-labeled levothyroxine content in the tablets .
Conclusion
While the FDA has established protocols to ensure the bioequivalence of generic levothyroxine products, clinical studies and real-world evidence suggest that these products may not always be interchangeable, particularly in vulnerable populations such as children with severe congenital hypothyroidism. Healthcare providers should exercise caution when substituting levothyroxine formulations and consider monitoring TSH levels and adjusting doses as necessary to ensure optimal treatment outcomes.
Sources and full results
Most relevant research papers on this topic